Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is new capsule form. T-1101 capsule IND application has been approved by FDA in Nov, 2020 and further by TFDA in Dec, 2020. T-1101: T-1101 Phase I trial is the first-in-human study conducted to evaluate the safety and tolerability of T-1101 capsule in patients with solid …

Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1101 capsule on Nov. 2021, to initiate phase I clinical trial. T-1101: T-1101 acts through disrupting the interaction between Hec1 and Nek2 to leads to tumor cells apoptosis. T-1101 demonstrated potent anti-cancer activity in different mouse xenograft models of human cancers, including liver and triple negative breast cancer. In …

T-1101, oral powder for constitution (OPC), from Taivex has completed the phase I trial in Oct, 2019. Total 21 patients have received T-1101 (Tosylate) OPC treatment in 4 clinical trial centers. According to the Phase clinical data, T-1101 has initially proved its safety and efficacy. Taivex will continue the development of T-1101 to further clinical trial with oral capsule form …

Taivex Therapeutics Corp. (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1301 (formerly, DBPR216), a potential anti-cancer developmental drug candidate, effective on April 8. T-1301 is a novel small molecular multi-target tyrosine kinase inhibitor (TKI), which is orally available and exhibited potent inhibitory efficacy against both wild type and mutant forms of …